Get the Stockscreener App
2.38
0.42%
0.010
After Hours:
2.38
Spero Therapeutics Inc stock is traded at $2.38, with a volume of 104.19K.
It is up +0.42% in the last 24 hours and down -5.18% over the past month.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
See More
Previous Close:
$2.37
Open:
$2.37
24h Volume:
104.19K
Relative Volume:
0.31
Market Cap:
$134.09M
Revenue:
$76.19M
Net Income/Loss:
$-1.61M
P/E Ratio:
238.00
EPS:
0.01
Net Cash Flow:
$28.98M
1W Performance:
+3.48%
1M Performance:
-5.18%
6M Performance:
+0.85%
1Y Performance:
+195.14%
1-Day Range:
$2.315
$2.41
1-Week Range:
$2.275
$2.43
52-Week Range:
$0.5052
$3.22
Spero Therapeutics Inc Stock (SPRO) Company Profile
Name
Spero Therapeutics Inc
Sector
Industry
Phone
857-242-1600
Address
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Compare SPRO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRO
Spero Therapeutics Inc
|
2.38 | 133.52M | 76.19M | -1.61M | 28.98M | 0.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-23-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-01-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-22-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Sep-29-20 | Initiated | Evercore ISI | Outperform |
| Nov-05-19 | Reiterated | H.C. Wainwright | Buy |
| Sep-09-19 | Initiated | Janney | Buy |
| Feb-09-18 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-27-17 | Initiated | BofA/Merrill | Neutral |
| Nov-27-17 | Initiated | Oppenheimer | Outperform |
| Nov-27-17 | Initiated | Stifel | Buy |
View All
Spero Therapeutics Inc Stock (SPRO) Latest News
Spero Therapeutics: Tebipenem’s FDA Path Supports A Speculative Buy (NASDAQ:SPRO) - Seeking Alpha
Esther Rajavelu Sells 87,917 Shares of Spero Therapeutics (NASDAQ:SPRO) Stock - MarketBeat
Keutzer, Spero Therapeutics COO, sells $44k in shares - Investing.com
Spero Therapeutics CEO sells $207k in stock By Investing.com - Investing.com Canada
Keutzer, Spero Therapeutics COO, sells $44k in shares By Investing.com - Investing.com Canada
Spero Therapeutics CEO sells $207k in stock - Investing.com
Aug Breakouts: What drives Spero Therapeutics Incs stock priceEarnings Summary Report & Safe Entry Zone Tips - baoquankhu1.vn
Spero Therapeutics (NASDAQ:SPRO) Insider Sells 18,442 Shares - MarketBeat
Spero Therapeutics (NASDAQ:SPRO) Stock Price Crosses Below 200 Day Moving AverageWhat's Next? - MarketBeat
Spero therapeutics exec Rajavelu sells $40k in shares By Investing.com - Investing.com Australia
Spero therapeutics exec Rajavelu sells $40k in shares - Investing.com
Spero Therapeutics announces board resignation and SEC investigation closure By Investing.com - Investing.com Nigeria
Spero Therapeutics Co-Founder Resigns From Board Roles - TipRanks
SEC ends Spero Therapeutics (NASDAQ: SPRO) probe as director steps down - Stock Titan
SEC Enforcement Action Against Former Spero Executives: Individual Liability For Misleading FDA-Related Disclosures - marketscreener.com
SEC Settlement Resolves Past Disclosure Issues for Spero Therapeutics - AD HOC NEWS
Spero Therapeutics announces inducement grant under Nasdaq listing rule - MSN
Momentum Shift: What is Spero Therapeutics Incs valuation compared to sector2025 Performance Recap & Daily Profit Maximizing Tips - baoquankhu1.vn
Insider Buy: Is Spero Therapeutics Inc stock overvalued by current metricsJuly 2025 EndofMonth & Low Drawdown Investment Ideas - Bộ Nội Vụ
Stock Market Recap: Will Spero Therapeutics Inc. stock reach all time highs in 20252025 Trading Volume Trends & Stock Portfolio Risk Management - Bộ Nội Vụ
Spero Therapeutics (NASDAQ:SPRO) Raised to "Buy" at Wall Street Zen - MarketBeat
Will Spero Therapeutics Inc. (2HA) stock sustain bullish trend into 2025 - ulpravda.ru
Is Spero Therapeutics Inc. (2HA) stock protected from inflationJuly 2025 Levels & Fast Gain Swing Trade Alerts - ulpravda.ru
Will Spero Therapeutics Inc. stock benefit from upcoming earnings reports2025 Trade Ideas & Free Expert Verified Stock Movement Alerts - Улправда
3 Promising Penny Stocks With Market Caps Up To $300M - simplywall.st
Spero Therapeutics (NASDAQ:SPRO) Downgraded by Wall Street Zen to Hold - MarketBeat
What analysts say about Spero Therapeutics Inc stockLong-Term Growth Stocks & Free Unmatched Market Gains - earlytimes.in
Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below 200-Day Moving Average – Here’s What Happened - Defense World
Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below 200-Day Moving AverageHere's What Happened - MarketBeat
Spero Therapeutics, Inc. (NASDAQ:SPRO) Sees Large Growth in Short Interest - MarketBeat
Book value per share of Spero Therapeutics, Inc. – BER:2HA - TradingView — Track All Markets
Spero Therapeutics (STU:2HA) EV-to-OCF : -2.75 (As of Dec. 24, 2025) - GuruFocus
Spero Therapeutics (NASDAQ:SPRO) Stock Price Crosses Below 200 Day Moving Average – Time to Sell? - Defense World
Will Spero Therapeutics Inc. stock reach all time highs in 2025Inflation Watch & Growth Oriented Trade Recommendations - Улправда
Stop Loss: Will Spero Therapeutics Inc. stock reach all time highs in 2025Inflation Watch & Reliable Price Breakout Signals - ulpravda.ru
GSK, Spero Therapeutics resubmits NDA for tebipenem HBr as oral option for complicated urinary tract infections - Contemporary OB/GYN
GSK Resubmits NDA, Triggering Milestone for Spero Therapeutics - TipRanks
Spero Therapeutics Announces NDA Resubmission for Tebipenem HBr - TradingView — Track All Markets
Spero Therapeutics Announces GSK's NDA Resubmission for Tebipenem HBr, Triggering $25 Million Milestone Payment - Quiver Quantitative
Spero Announces NDA Resubmission of Tebipenem HBr by GSK to - GlobeNewswire
How geopolitical risks impact Spero Therapeutics Inc. (2HA) stockMarket Performance Report & Short-Term Trading Opportunity Alerts - DonanımHaber
Total debt per share of Spero Therapeutics, Inc. – FWB:2HA - TradingView — Track All Markets
Is Spero Therapeutics (NASDAQ:SPRO) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Spero Therapeutics (SPRO) price target decreased by 20.00% to 4.08 - MSN
Spero Therapeutics (NASDAQ:SPRO) Upgraded to "Buy" at Wall Street Zen - MarketBeat
Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates - sharewise.com
Spero Therapeutics (NASDAQ:SPRO) Stock Rating Lowered by Wall Street Zen - MarketBeat
Can Spero Therapeutics Inc. (2HA) stock test all time highsMarket Risk Report & Free Low Drawdown Momentum Trade Ideas - Newser
Will Spero Therapeutics Inc. (2HA) stock benefit from sector leadership2025 Top Gainers & Free Weekly Watchlist of Top Performers - Newser
Why Spero Therapeutics Inc. stock is popular among millennials2025 Market Overview & Community Consensus Picks - Newser
Spero Therapeutics Inc Stock (SPRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):